Rosa A. Maldonado to Leishmaniasis, Cutaneous
This is a "connection" page, showing publications Rosa A. Maldonado has written about Leishmaniasis, Cutaneous.
Connection Strength
2.115
-
Rodriguez F, John SF, Iniguez E, Montalvo S, Michael K, White L, Liang D, Olaleye OA, Maldonado RA. In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors. Antimicrob Agents Chemother. 2020 05 21; 64(6).
Score: 0.747
-
Iniguez E, Schocker NS, Subramaniam K, Portillo S, Montoya AL, Al-Salem WS, Torres CL, Rodriguez F, Moreira OC, Acosta-Serrano A, Michael K, Almeida IC, Maldonado RA. An a-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major. PLoS Negl Trop Dis. 2017 Oct; 11(10):e0006039.
Score: 0.625
-
Iniguez E, Varela-Ramirez A, Mart?nez A, Torres CL, S?nchez-Delgado RA, Maldonado RA. Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis. Acta Trop. 2016 Dec; 164:402-410.
Score: 0.580
-
Rodriguez F, Iniguez E, Pena Contreras G, Ahmed H, Costa TEMM, Skouta R, Maldonado RA. Development of Thiophene Compounds as Potent Chemotherapies for the Treatment of Cutaneous Leishmaniasis Caused by Leishmania major. Molecules. 2018 07 04; 23(7).
Score: 0.164